About Lutathera®

Introducing Lutathera®

Lutetium (177Lu) Oxodotreotide

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

 
 
 

*Not provided with LUTATHERA®. **Recommended composition L-Lysine HCl 25g is equivalent to 20.0g lysine and L-Arginine HCl 25g is equivalent to 20.7g arginine. †Equivalent to 14.4-20g lysine. ‡Equivalent to 14.9-20.7g arginine.

References: 1. LUTATHERA® Summary of Product Characteristics. January 2021. Available at: https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf Accessed April 2021. 2. Strosberg J, El-Haddad G, Wolin E et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. New Engl J Med. 2017;376(2): 127–135. 3. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24(4): 389–427. 4. Ambrosini V, Kunikowska J, Baudin E et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021;146: 56–73. 5. Hicks RJ, Kwekkeboom DJ, Krenning E et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology. 2017;105(3): 295–309.